

[Cisplatin](#)

Essential medicine status

Section:

[8. Immunomodulators and antineoplastics](#) [8.2. Antineoplastics and supportive medicines](#) [8.2.1. Cytotoxic medicines](#)

ATC codes: [L01XA01](#)

EMLc

Indication

Malignant neoplasms of nasopharynx ICD11 code: [2C3B.Z](#)

INN

Cisplatin

Medicine type

Chemical agent

List type

Core

Formulations

Parenteral > General injections > IV: 50 mg per 50 mL ; 100 mg per 100 mL ; 10 mg per 10 mL ; 20 mg per 20 mL

EML status history

First added in 1984 ([TRS 722](#))

Changed in 2015 ([TRS 994](#))

Changed in 2019 ([TRS 1021](#))

Changed in 2021 ([TRS 1035](#))

Sex

All

Age

Also recommended for children

Therapeutic alternatives

The recommendation is for this specific medicine

Patent information

Patents have expired in most jurisdictions

Read more [about patents](#).

Tags

Cancer

Wikipedia

[Cisplatin](#)

DrugBank

[Cisplatin](#)

Summary of evidence and Expert Committee recommendations

The Expert Committee recommended the addition of new strength formulations of cisplatin IV injection (10 mg/10 mL and 20 mg/20 mL) to the EML and EMLc.